Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | UTHR | Common Stock | Options Exercise | $0 | +1.08K | +9.73% | $0.00 | 12.2K | Jul 8, 2022 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | UTHR | Restricted Stock Unit | Options Exercise | $0 | -1.08K | -100% | $0.00* | 0 | Jul 8, 2022 | Common Stock | 1.08K | $0.00 | Direct | F1, F3, F4 |
Id | Content |
---|---|
F1 | This amendment corrects an overstatement of the number of restricted stock units that vested on July 8, 2022, and the number of resulting shares of common stock received by the reporting person. In both cases, the original number reported (3,230 restricted stock units / shares of common stock) has been corrected (1,080 restricted stock units / shares of common stock). |
F2 | Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock. |
F3 | Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. |
F4 | Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. |